尾加压素Ⅱ对大鼠骨髓源内皮祖细胞的作用及其分子机制
|
摘要
目的：探讨尾加压素Ⅱ(UⅡ)对大鼠骨髓源内皮祖细胞(EPCs)的作用及其分子机制。
方法：选体重110-150g的雄性SD大鼠,分离获取骨髓单核细胞,在内皮细胞培养基中培养诱导,观察细胞生长形态变化,免疫荧光染色鉴定表面标志以及Dil-acLDL摄取试验细胞功能学检测。用RT-PCR、Western Blotting和免疫荧光检测等方法确定GPR14在EPCs上基因和蛋白水平的表达。利用Transwell小室进行趋化实验,观察不同浓度UⅡ对EPCs迁移的影响,检测UⅡ作用EPCs后,RhoA和GTP结合RhoA、MLC磷酸化水平,以及GPR14受体拮抗剂Urantide和Rho激酶抑制剂Y-27632对UⅡ诱导EPCs迁移的影响。CCK-8增殖实验观察不同浓度UⅡ对EPCs增殖的影响,检测UⅡ作用EPCs后,MAPK的激活状态,以及GPR14受体拮抗剂Urantide和MAPK抑制剂对UⅡ诱导EPCs增殖和MAPK磷酸化水平的影响。
结果：从细胞贴壁,伪足样突起,“集落”形成,到条索样结构以及呈典型铺路石样外观,表现内皮祖细胞生长特性。免疫荧光染色鉴定提示CD133、VEGFR-2、vWF表达阳性。摄取DiI-acLDL结合FITC-UEA-1试验,FITC-UEA-1和DiI-acLDL双染色阳性。RT-PCR、Western Blotting和免疫荧光染色等方法检测显示,在分子和蛋白水平EPCs均有GPR14表达,免疫荧光检测GPR14在EPCs膜上染色阳性。UⅡ诱导的EPCs迁移呈典型的剂量依赖型,Urantide和Rho激酶抑制剂Y-27632抑制UⅡ对EPCs的趋化作用(p<0.05,vs.UⅡ组)。UⅡ诱导GTP结合RhoA增加,和对照组相比,UⅡ(10-8M)诱导RhoA和GTP结合RhoA增加约3倍(p<0.05,UⅡ组vscontrol组),GPR14抑制剂Urantide可以显著抑制这种效应(p<0.01 vs.UⅡ组),Rho激酶抑制剂Y-27632抑制作用不明显(p>0.05 vs.the 10-8M UⅡgroup)。UⅡ诱导增加MLC磷酸化增加,和对照组相比,UⅡ诱导增加MLC磷酸化增加约2.5倍(p<0.05,vscontrol组),GPR14抑制剂Urantide和Rho激酶抑制剂Y-27632均可显著抑制这种效应(p<0.05,vs.UⅡ组)。UⅡ对EPCs促增殖作用呈剂量依赖型,Urantide、SB203580和PD98059对UⅡ诱导的促增殖效应有显著抑制作用,抑制程度分别为62.4%、54.3%、和49.2%(all p<0.05 vs.the10-8M UⅡ组)。但SAPK/JNK抑制剂SP600125对增殖无抑制作用,且有增强趋势,但无显著差异(p>0.05 vs.the 10-8M UⅡ组)。和对照组相比,UⅡ组p38MAPK磷酸化程度显著增高(p<0.05 vscontrol组),这种效应可以被GPR14受体拮抗剂Urantide完全阻断(p<0.05 vs.UⅡ组),被p38MAPK抑制剂SB203580部分阻断(p<0.05 vs.UⅡ组)。和对照组相比,UⅡ组p44/42MAPK磷酸化程度显著增高(p<0.05 vscontrol组),这种效应可以被Urantide完全阻断(p<0.05 vs.UⅡ组),被p44/42MAPK抑制剂PD98059部分阻断(p<0.05 vs.UⅡ组)
结论：1、所培养的细胞证实为内皮祖细胞,EPCs表达UⅡ特异性受体GPR14受体。2、UⅡ是一种新的内皮祖细胞趋化肽,趋化作用呈剂量依赖性,其机制与RhoA/Rho激酶信号通路相关。3、尾加压素Ⅱ促进骨髓源EPCs增殖,其机制与ERK1/2和P38MAPK的活化有关。
Objective:To explore regulating effects of UrotensinⅡ(UII) on endothelial progenitor cells (EPCs) derived from rat bone marrow and its potential intracellular singal pathways.
Method:Bone marrow from the femurs of the SD rats was removed and mononuclear cells were isolated by density gradient centrifugation. Cells were resuspended by EGM-MV BulletKit system and incubated at 37℃in 100% humidified air with 5% CO2. Morphology and growth characteristics of cells were observed by microscopy. Immunohistochemistry staining were performed to detect for the expressoion of von Willebrand factor (vWF) and CD133 and VEGFR-2. Experiment of uptaking DIL-ac-LDL and combining FITC-Lectin-UEA-1 was observed by laser sanning confocal microscope to identify endothelial cells characteristic. To better understand whether UII can regulate EPC function via a receptor-dependent pathway, RT-PCR and Western blot were performed to detect expression of the GPR14 in EPCs at mRNA and protein levels. Chemotaxis assays were performed using Transwell cell-culture chambers with UII (10-10-10-6 M). The activation of RhoA and the phosphorylation of myosin light chain (MLC) in EPCs were analyzed. The effets of Rho-kinase inhibitor Y-27632 and GPR14 receptor blocker Urantide to UII-induced migration of EPCs and the phosphorylation of MLC were observated. Proliferation assays were performed using WST-8 with UII (10-10-10-6M). The activation the phosphorylation of MAPK in EPCs were analyzed. The effets of MAPK inhibitor and GPR14 receptor blocker Urantide to UII-induced proliferation of EPCs and the phosphorylation of MAPK were observated.
Result:Parts of cells start attaching after 48 hours. The morphology formed the shuttle, triangle, the spindle or irregular form. The attached cells were able to form cells "colonies" and line up in the core-like structure from 4 to 8 days, and get close to coalesce and exhibite the typical cobble stone morphology. The cells were positively stained for CD133, VEGFR-2 and vWF. Fluorescence microscopy showed that adherent cells took up DiI-acLDL and bound FITC-Lectin-UEA-1. EPCs express GPR14 at mRNA and protein levels. Fluorescence microscopy showed that cells were positively stained for GPR14. UII induces migration of EPCs in a concen- tration-dependent manner in a certain extent. The cell count assay revealed that 1.5-, 2.1-,2.9-,2.3-and 1.6-fold increase was detected in migration of EPCs induced by UII at the concentration of 10-10 M,10-9 M,10-8 M,10-7 M and 10-6 M, respectively (all p＜0.05 vs. control group). The Rho-kinase inhibitor, Y-27632 (10μM), abolished UII (10-8 M)-induced migration of EPCs (p＜0.05 vs. control group, p＜0.05 vs. UII group). UII (10-8 M) induced 3-fold increase in the amount of active GTP-bound RhoA in EPCs (p＜0.05, UII group vs. control group), and Urantide (10μM) abolished the effect of UII (p＜0.01 vs. UII group). UII induced 2.5-fold increase in MLC phosphorylation(p＜0.05, UII group vs. control group) which was blocked by Y-27632 (10μM) and Urantide(10μM) (p＜0.05, Y-27632 group vs. UII group). UII promotes proliferation of EPCs in a concentration-dependent manner in a certain range, and treatment with a GPR14 inhibitor or MAPK inhibitors suppressed UII-induced EPC proliferation. Results of the WST-8 assay showed 14.2%,48.8%,69.2%,46.3%, and 27.3% increases in proliferation in response to treatment with UII at concentrations of 10-10M,10-9M, 10-8M,10-7 M, and 10-6 M, respectively (all p＜0.05 vs. control group). The proliferative effect of UII on EPCs was inhibited by 62.4%,54.3%, and 49.2% in response to Urantide, SB203580, and PD98059, respectively. But the proliferative effect of UII on EPCs wasn't inhibited by SP600125(p＞0.05 vs. the 10-8 M UII group). Treatment with UII (10-8 M) increased the phosphorylation of p38MAPK (p＜0.05 vs. control group). This effect was inhibited by the inhibitors SB203580 (10μM) (p＜0.05 vs. UII group). Treatment with UII (10-8M) increased the phosphorylation of p44/42MAPK (p＜0.05 vs. control group). This effect was inhibited by the inhibitors PD98059 (10μM) (p＜0.05 vs. UII group).
Conclusion:1.Cultured cells were considered EPCs which express specific receptor GPR14 of UII.2. UII induces migration of EPCs in a concentration-dependent manner. UII-induced migration is mediated by activation of the RhoA/Rho kinase pathway. 3.UII induces migration of EPCs in a concentration-dependent manner. UII-induced migration is mediated by activation of the RhoA/Rho kinase pathway.
方法：选体重110-150g的雄性SD大鼠,分离获取骨髓单核细胞,在内皮细胞培养基中培养诱导,观察细胞生长形态变化,免疫荧光染色鉴定表面标志以及Dil-acLDL摄取试验细胞功能学检测。用RT-PCR、Western Blotting和免疫荧光检测等方法确定GPR14在EPCs上基因和蛋白水平的表达。利用Transwell小室进行趋化实验,观察不同浓度UⅡ对EPCs迁移的影响,检测UⅡ作用EPCs后,RhoA和GTP结合RhoA、MLC磷酸化水平,以及GPR14受体拮抗剂Urantide和Rho激酶抑制剂Y-27632对UⅡ诱导EPCs迁移的影响。CCK-8增殖实验观察不同浓度UⅡ对EPCs增殖的影响,检测UⅡ作用EPCs后,MAPK的激活状态,以及GPR14受体拮抗剂Urantide和MAPK抑制剂对UⅡ诱导EPCs增殖和MAPK磷酸化水平的影响。
结果：从细胞贴壁,伪足样突起,“集落”形成,到条索样结构以及呈典型铺路石样外观,表现内皮祖细胞生长特性。免疫荧光染色鉴定提示CD133、VEGFR-2、vWF表达阳性。摄取DiI-acLDL结合FITC-UEA-1试验,FITC-UEA-1和DiI-acLDL双染色阳性。RT-PCR、Western Blotting和免疫荧光染色等方法检测显示,在分子和蛋白水平EPCs均有GPR14表达,免疫荧光检测GPR14在EPCs膜上染色阳性。UⅡ诱导的EPCs迁移呈典型的剂量依赖型,Urantide和Rho激酶抑制剂Y-27632抑制UⅡ对EPCs的趋化作用(p<0.05,vs.UⅡ组)。UⅡ诱导GTP结合RhoA增加,和对照组相比,UⅡ(10-8M)诱导RhoA和GTP结合RhoA增加约3倍(p<0.05,UⅡ组vscontrol组),GPR14抑制剂Urantide可以显著抑制这种效应(p<0.01 vs.UⅡ组),Rho激酶抑制剂Y-27632抑制作用不明显(p>0.05 vs.the 10-8M UⅡgroup)。UⅡ诱导增加MLC磷酸化增加,和对照组相比,UⅡ诱导增加MLC磷酸化增加约2.5倍(p<0.05,vscontrol组),GPR14抑制剂Urantide和Rho激酶抑制剂Y-27632均可显著抑制这种效应(p<0.05,vs.UⅡ组)。UⅡ对EPCs促增殖作用呈剂量依赖型,Urantide、SB203580和PD98059对UⅡ诱导的促增殖效应有显著抑制作用,抑制程度分别为62.4%、54.3%、和49.2%(all p<0.05 vs.the10-8M UⅡ组)。但SAPK/JNK抑制剂SP600125对增殖无抑制作用,且有增强趋势,但无显著差异(p>0.05 vs.the 10-8M UⅡ组)。和对照组相比,UⅡ组p38MAPK磷酸化程度显著增高(p<0.05 vscontrol组),这种效应可以被GPR14受体拮抗剂Urantide完全阻断(p<0.05 vs.UⅡ组),被p38MAPK抑制剂SB203580部分阻断(p<0.05 vs.UⅡ组)。和对照组相比,UⅡ组p44/42MAPK磷酸化程度显著增高(p<0.05 vscontrol组),这种效应可以被Urantide完全阻断(p<0.05 vs.UⅡ组),被p44/42MAPK抑制剂PD98059部分阻断(p<0.05 vs.UⅡ组)
结论：1、所培养的细胞证实为内皮祖细胞,EPCs表达UⅡ特异性受体GPR14受体。2、UⅡ是一种新的内皮祖细胞趋化肽,趋化作用呈剂量依赖性,其机制与RhoA/Rho激酶信号通路相关。3、尾加压素Ⅱ促进骨髓源EPCs增殖,其机制与ERK1/2和P38MAPK的活化有关。
Objective:To explore regulating effects of UrotensinⅡ(UII) on endothelial progenitor cells (EPCs) derived from rat bone marrow and its potential intracellular singal pathways.
Method:Bone marrow from the femurs of the SD rats was removed and mononuclear cells were isolated by density gradient centrifugation. Cells were resuspended by EGM-MV BulletKit system and incubated at 37℃in 100% humidified air with 5% CO2. Morphology and growth characteristics of cells were observed by microscopy. Immunohistochemistry staining were performed to detect for the expressoion of von Willebrand factor (vWF) and CD133 and VEGFR-2. Experiment of uptaking DIL-ac-LDL and combining FITC-Lectin-UEA-1 was observed by laser sanning confocal microscope to identify endothelial cells characteristic. To better understand whether UII can regulate EPC function via a receptor-dependent pathway, RT-PCR and Western blot were performed to detect expression of the GPR14 in EPCs at mRNA and protein levels. Chemotaxis assays were performed using Transwell cell-culture chambers with UII (10-10-10-6 M). The activation of RhoA and the phosphorylation of myosin light chain (MLC) in EPCs were analyzed. The effets of Rho-kinase inhibitor Y-27632 and GPR14 receptor blocker Urantide to UII-induced migration of EPCs and the phosphorylation of MLC were observated. Proliferation assays were performed using WST-8 with UII (10-10-10-6M). The activation the phosphorylation of MAPK in EPCs were analyzed. The effets of MAPK inhibitor and GPR14 receptor blocker Urantide to UII-induced proliferation of EPCs and the phosphorylation of MAPK were observated.
Result:Parts of cells start attaching after 48 hours. The morphology formed the shuttle, triangle, the spindle or irregular form. The attached cells were able to form cells "colonies" and line up in the core-like structure from 4 to 8 days, and get close to coalesce and exhibite the typical cobble stone morphology. The cells were positively stained for CD133, VEGFR-2 and vWF. Fluorescence microscopy showed that adherent cells took up DiI-acLDL and bound FITC-Lectin-UEA-1. EPCs express GPR14 at mRNA and protein levels. Fluorescence microscopy showed that cells were positively stained for GPR14. UII induces migration of EPCs in a concen- tration-dependent manner in a certain extent. The cell count assay revealed that 1.5-, 2.1-,2.9-,2.3-and 1.6-fold increase was detected in migration of EPCs induced by UII at the concentration of 10-10 M,10-9 M,10-8 M,10-7 M and 10-6 M, respectively (all p＜0.05 vs. control group). The Rho-kinase inhibitor, Y-27632 (10μM), abolished UII (10-8 M)-induced migration of EPCs (p＜0.05 vs. control group, p＜0.05 vs. UII group). UII (10-8 M) induced 3-fold increase in the amount of active GTP-bound RhoA in EPCs (p＜0.05, UII group vs. control group), and Urantide (10μM) abolished the effect of UII (p＜0.01 vs. UII group). UII induced 2.5-fold increase in MLC phosphorylation(p＜0.05, UII group vs. control group) which was blocked by Y-27632 (10μM) and Urantide(10μM) (p＜0.05, Y-27632 group vs. UII group). UII promotes proliferation of EPCs in a concentration-dependent manner in a certain range, and treatment with a GPR14 inhibitor or MAPK inhibitors suppressed UII-induced EPC proliferation. Results of the WST-8 assay showed 14.2%,48.8%,69.2%,46.3%, and 27.3% increases in proliferation in response to treatment with UII at concentrations of 10-10M,10-9M, 10-8M,10-7 M, and 10-6 M, respectively (all p＜0.05 vs. control group). The proliferative effect of UII on EPCs was inhibited by 62.4%,54.3%, and 49.2% in response to Urantide, SB203580, and PD98059, respectively. But the proliferative effect of UII on EPCs wasn't inhibited by SP600125(p＞0.05 vs. the 10-8 M UII group). Treatment with UII (10-8 M) increased the phosphorylation of p38MAPK (p＜0.05 vs. control group). This effect was inhibited by the inhibitors SB203580 (10μM) (p＜0.05 vs. UII group). Treatment with UII (10-8M) increased the phosphorylation of p44/42MAPK (p＜0.05 vs. control group). This effect was inhibited by the inhibitors PD98059 (10μM) (p＜0.05 vs. UII group).
Conclusion:1.Cultured cells were considered EPCs which express specific receptor GPR14 of UII.2. UII induces migration of EPCs in a concentration-dependent manner. UII-induced migration is mediated by activation of the RhoA/Rho kinase pathway. 3.UII induces migration of EPCs in a concentration-dependent manner. UII-induced migration is mediated by activation of the RhoA/Rho kinase pathway.
引文
[1]Endemann DH, Schiffrin EL. Endothelial dysfunction. J Am Soc Nephrol 2004,15(8):1983-1992.
[2]Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells:the missing link in atherosclerosis? J Mol Med 2004,82(10):671-677.
[3]Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997,275(5302):964-967.
[4]Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003,9(6):702-712.
[5]Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999,401(6750):282-286.
[6]Watanabe T, Arita S, Shiraishi Y, et al. Human urotensin Ⅱ promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem 2009,16(5):550-563.
[7]Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin Ⅱ on human endothelial cells. Atherosclerosis 2006,188(2):260-264.
[8]Wang H, Mehta JL, Chen K, et al. Human urotensin Ⅱ modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004,44(5):577-581.
[9]Cirillo P, De Rosa S, Pacileo M, et al. Human urotensin Ⅱ induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells:an emerging role for urotensin Ⅱ in cardiovascular disease. J Thromb Haemost 2008,6(5):726-736.
[10]Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999,85(3):221-228.
[11]Murohara T. Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. Trends Cardiovasc Med 2001,11(8):303-307.
[12]Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998,92(2):362-367.
[13]Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007,109(5):1801-1809.
[14]Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001,89(1):E1-7.
[15]Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993,69(5):508-517.
[16]Sharpe EE,3rd, Teleron AA, Li B, et al.Price J, et al. The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am J Pathol 2006,168(5): 1710-1721.
[17]Casamassimi A, Balestrieri ML, Fiorito C, et al. Comparison between total endothelial progenitor cell isolation versus enriched Cd133+culture. J Biochem 2007,141(4):503-511.
[18]Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997,90(12):5002-5012.
[19]Mori M, Sugo T, Abe M, et al. Urotensin Ⅱ is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999,265(1):123-129.
[20]Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin Ⅱ:receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000,131(3):441-446.
[21]Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin Ⅱ and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001,19(12):2185-2190.
[22]Douglas SA, Ohlstein EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000,10(6):229-237.
[23]Maguire JJ, Davenport AP. Is urotensin-Ⅱ the new endothelin? Br J Pharmacol 2002, 137(5):579-588.
[24]Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-Ⅱ in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004,25(10):1767-1774.
[25]Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin Ⅱ and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004, 176(1):117-123.
[26]Douglas SA, Naselsky D, Ao Z, et al. Identification and pharmacological characterization of native, functional human urotensin-Ⅱ receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 2004,142(6):921-932.
[27]Guerrini R, Camarda V, Marzola E, et al. Structure-activity relationship study on human urotensin Ⅱ. J Pept Sci 2005,11(2):85-90.
[28]Liu Q, Pong SS, Zeng Z, et al. Identification of urotensin Ⅱ as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999, 266(1):174-178.
[29]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001,19(12):2191-2196.
[30]Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet 2002,359(9322):1990-1997.
[31]Richards AM, Charles C. Urotensin Ⅱ in the cardiovascular system. Peptides 2004,25(10): 1795-1802.
[32]Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-Ⅱ immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003,285(4): H1576-1581.
[33]Hongfang J, Cong B, Zhao B, et al. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 2006,78(12):1299-1309.
[34]Johns DG, Ao Z, Naselsky D, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy:effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004,370(4):238-250.
[35]Birker-Robaczewska M, Boukhadra C, Studer R, et al. The expression of urotensin Ⅱ receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 2003,23(4): 289-305.
[36]Segain JP, Rolli-Derkinderen M, Gervois N, et al. Urotensin Ⅱ is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007,179(2):901-909.
[37]Yang Y, Marcello M, Endris V, et al. MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp Cell Res 2006,312(12):2379-2393.
[38]Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996,15(9):2208-2216.
[39]Bhadriraju K, Elliott JT, Nguyen M, et al. Quantifying myosin light chain phosphorylation in single adherent cells with automated fluorescence microscopy. BMC Cell Biol 2007,8:43.
[40]Hartel FV, Rodewald CW, Aslam M, et al. Extracellular ATP induces assembly and activation of the myosin light chain phosphatase complex in endothelial cells. Cardiovasc Res 2007, 74(3):487-496.
[41]Zhu YC, Zhu YZ, Moore PK. The role of urotensin Ⅱ in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006,148(7):884-901.
[42]Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin Ⅱ-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001, 88(11):1102-1104.
[43]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001,104(1):16-18.
[44]Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003,9(11):1370-1376.
[45]Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007,49(7):741-752.
[46]Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003,348(7):593-600.
[47]Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999,340(2):115-126.
[48]Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003, 23(7):1143-1151.
[49]Hassan GS, Douglas SA, Ohlstein EH, et al. Expression of urotensin-Ⅱ in human coronary atherosclerosis. Peptides 2005,26(12):2464-2472.
[50]Gendron G, Simard B, Gobeil F, et al. Human urotensin-Ⅱ enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Physiol Pharmacol 2004,82(1):16-21.
[51]Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003,108(4):457-463.
[52]Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002,420(6916):629-635.
[53]Vicente-Manzanares M, Cabrero JR, Rey M, et al. A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1 alpha-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J Immunol 2002,168(1):400-410.
[54]Zhang YG, Li YG, Liu BG, et al. Urotensin Ⅱ accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin 2007,28(1):36-43.
[55]Matsusaka S, Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin Ⅱ. Naunyn Schmiedebergs Arch Pharmacol 2006,373(5):381-386.
[56]Saetrum Opgaard O, Nothacker H, Ehlert FJ, et al. Human urotensin Ⅱ mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000,406(2):265-271.
[57]Tasaki K, Hori M, Ozaki H, et al. Mechanism of human urotensin Ⅱ-induced contraction in rat aorta. J Pharmacol Sci 2004,94(4):376-383.
[58]Rossowski WJ, Cheng BL, Taylor JE, et al. Human urotensin Ⅱ-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase:inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002,438(3):159-170.
[59]Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin Ⅱ is raised in hypertension. J Hypertens 2004,22(7):1341-1344.
[60]Khan SQ, Bhandari SS, Quinn P, et al. Urotensin Ⅱ is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007, 117(3):323-328.
[61]Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-Ⅱ-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004,94(1):93-97.
[62]Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation 2002,106(23):2877-2880.
[63]Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin Ⅱ levels in patients with diabetes mellitus. Clin Sci (Lond) 2003,104(1):1-5.
[64]Zoccali C, Mallamaci F, Benedetto FA, et al. Urotensin Ⅱ and cardiomyopathy in end-stage renal disease. Hypertension 2008,51(2):326-333.
[65]Heller J, Schepke M, Neef M, et al. Increased urotensin Ⅱ plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002,37(6):767-772.
[66]Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of Urotensin-Ⅱ in preeclampsia-eclampsia:a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol 2005,120(1):33-38.
[67]Gruson D, Rousseau MF, Ahn SA, et al. Circulating urotensin Ⅱ levels in moderate to severe congestive heart failure:its relations with myocardial function and well established neurohormonal markers. Peptides 2006,27(6):1527-1531.
[68]Charles CJ, Rademaker MT, Richards AM, et al. Urotensin Ⅱ:evidence for cardiac, hepatic and renal production. Peptides 2005,26(11):2211-2214.
[69]Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin Ⅱ in heart failure. Lancet 2002,360(9332):545-546.
[70]Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin Ⅱ and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006,19(5):505-510.
[71]Gold SJ, Thompson JP, Williams JP, et al. Does cigarette smoking increase plasma urotensin Ⅱ concentrations? Eur J Clin Pharmacol 2007,63(3):253-257.
[72]Li DY, Chen HJ, Staples ED, et al. Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions. J Cardiovasc Pharmacol Ther 2002,7(3):147-153.
[73]Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004,94(3):370-376.
[74]Chen H, Li D, Sawamura T, et al. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits:modulation by losartan. Biochem Biophys Res Commun 2000, 276(3):1100-1104.
[75]Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 2004,43(1):68-76.
[76]Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999,79(1): 215-262.
[77]Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin Ⅱ on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003,93(3):246-253.
[78]Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin Ⅱ causes fatal circulatory collapse in anesthesized monkeys in vivo:a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 2004,286(3):H830-836.
[79]Djordjevic T, BelAiba RS, Bonello S, et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005, 25(3):519-525.
[80]Tamura K, Okazaki M, Tamura M, et al. Urotensin Ⅱ-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells:involvement of cell adhesion-mediated integrin signaling. Life Sci 2003,72(9):1049-1060.
[81]孙正浩,张孙曦,李菊香,等.钙信号在尾加压素Ⅱ促血管平滑肌增殖中的作用[J].北京大学学报(医学版)2002,34(3)：261-265.
[1]Balment RJ, Song W, Ashton N. Urotensin Ⅱ:ancient hormone with new functions in vertebrate body fluid regulation. Ann N Y Acad Sci 2005,1040:66-73.
[2]Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999,401(6750):282-286.
[3]Douglas SA, Naselsky D, Ao Z, et al. Identification and pharmacological characterization of native, functional human urotensin-Ⅱ receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 2004,142(6):921-932.
[4]Mori M, Sugo T, Abe M, et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999,265(1):123-129.
[5]Douglas SA, Ohlstein EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000,10(6):229-237.
[6]Russell FD, Kearns P, Toth I, et al. Urotensin-Ⅱ-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 2004,310(1):209-214.
[7]Wenyi Z, Suzuki S, Hirai M, et al. Role of urotensin Ⅱ gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003,46(7):972-976.
[8]Protopopov A, Kashuba V, Podowski R, et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet 2000,88(3-4):312-313.
[9]Guerrini R, Camarda V, Marzola E, et al. Structure-activity relationship study on human urotensin Ⅱ. J Pept Sci 2005,11(2):85-90.
[10]Maguire JJ, Davenport AP. Is urotensin-Ⅱ the new endothelin? Br J Pharmacol 2002,137(5): 79-588.
[11]Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-Ⅱ in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004,25(10):1767-1774.
[12]Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin Ⅱ and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004,176(1): 17-123.
[13]Xu S, Jiang H, Wu B, et al. Urotensin Ⅱ induces migration of endothelial progenitor cells via activation of the RhoA/Rho kinase pathway. Tohoku J Exp Med 2009,219(4):283-288.
[14]Richards AM, Charles C.:Urotensin Ⅱ in the cardiovascular system. Peptides 2004,25(10): 1795-1802.
[15]Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-Ⅱ immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003,285(4): 1576-1581.
[16]Hongfang J, Cong B, Zhao B, et al. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 2006,78(12):1299-1309.
[17]Johns DG, Ao Z, Naselsky D, et al.Herold CL, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy:effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004,370(4):238-250.
[18]Birker-Robaczewska M, Boukhadra C, Studer R, et al. The expression of urotensin Ⅱ receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 2003,23(4): 89-305.
[19]Segain JP, Rolli-Derkinderen M, Gervois N, et al. Urotensin Ⅱ is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007,179(2):901-909.
[20]Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin Ⅱ is raised in hypertension. J Hypertens 2004,22(7):1341-1344.
[21]Khan SQ, Bhandari SS, Quinn P, et al. Urotensin Ⅱ is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007,117(3): 23-328.
[22]Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-Ⅱ-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004,94(1):93-97.
[23]Ng LL, Loke I, O'Brien RJ, et al.S Plasma urotensin in human systolic heart failure. Circulation 2002,106(23):2877-2880.
[24]Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin Ⅱ levels in patients with diabetes mellitus. Clin Sci (Lond) 2003,104(1):1-5.
[25]Zoccali C, Mallamaci F, Benedetto FA, et al. Urotensin Ⅱ and cardiomyopathy in end-stage renal disease. Hypertension 2008,51(2):326-333.
[26]Heller J, Schepke M, Neef M, et al. Increased urotensin Ⅱ plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002,37(6):767-772.
[27]Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of Urotensin-Ⅱ in preeclampsia-clampsia:a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol 2005,120(1): 3-38.
[28]Gruson D, Rousseau MF, Ahn SA, et al. Circulating urotensin Ⅱ levels in moderate to severe congestive heart failure:its relations with myocardial function and well established neurohormonal markers. Peptides 2006,27(6):1527-1531.
[29]Charles CJ, Rademaker MT, Richards AM, et al. Urotensin Ⅱ:evidence for cardiac, hepatic and renal production. Peptides 2005,26(11):2211-2214.
[30]Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin Ⅱ in heart failure. Lancet 2002,360(9332):545-546.
[31]Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin Ⅱ and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006,19(5):505-510.
[32]Gold SJ, Thompson JP, Williams JP, et al. Does cigarette smoking increase plasma urotensin Ⅱ concentrations? Eur J Clin Pharmacol 2007,63(3):253-257.
[33]Gibson A. Complex effects of Gillichthys urotensin Ⅱ on rat aortic strips. Br J Pharmacol 1987, 91(1):205-212.
[34]Yoshimoto S, Ishizaki Y, Sasaki T, et al. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991,22(3):378-383.
[35]Wagner OF, Christ G, Wojta J, et al.Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR:Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992,267(23):16066-16068.
[36]Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23(6):1427-1433.
[37]Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet 2002,359(9322):1990-1997.
[38]Hassan GS, Douglas SA, Ohlstein EH, et al. Expression of urotensin-Ⅱ in human coronary atherosclerosis. Peptides 2005,26(12):2464-2472.
[39]Kemp W, Krum H, Colman J, et al. Urotensin Ⅱ:a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007,27(9):1232-1239.
[40]Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 1998,95(26):15803-15808.
[41]Nothacker HP, Wang Z, McNeill AM, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999, 1(6):383-385.
[42]Shenouda A, Douglas SA, Ohlstein EH, et al. Localization of urotensin-Ⅱ immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002,50(7):885-889.
[43]Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin Ⅱ and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001,19(12):2185-2190.
[44]Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin Ⅱ and urotensin Ⅱ receptor in human diabetic nephropathy. Am J Kidney Dis 2004,44(5):826-831.
[45]Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin Ⅱ in patients on dialysis. Lancet 2001,358(9284):810-811.
[46]Mosenkis A, Danoff TM, Aiyar N, et al. Human urotensin Ⅱ in the plasma of anephric subjects. Nephrol Dial Transplant 2007,22(4):1269-1270.
[47]MacLean MR, Alexander D, Stirrat A, et al. Contractile responses to human urotensin-Ⅱ in rat and human pulmonary arteries:effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000,130(2):201-204.
[48]Djordjevic T, Gorlach A.:Urotensin-Ⅱ in the lung:a matter for vascular remodelling and pulmonary hypertension? Thromb Haemost 2007,98(5):952-962.
[49]Bottrill FE, Douglas SA, Hiley CR, et al. Human urotensin-Ⅱ is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000,130(8):1865-1870.
[50]Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000,131(7):1262-1274.
[51]Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin Ⅱ:receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000,131(3):441-446.
[52]Camarda V, Rizzi A, Calo G, et al. Effects of human urotensin Ⅱ in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 2002,365(2):141-149.
[53]Behm DJ, Harrison SM, Ao Z, et al. Deletion of the UT receptor gene results in the selective loss of urotensin-Ⅱ contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003,139(2):464-472.
[54]Ishihata A, Ogaki T, Aita T, et al. Role of prostaglandins in urotensin Ⅱ-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 2005,523(1-3):119-126.
[55]Lacza Z, D WB. Urotensin-Ⅱ is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 2006,78(23):2763-2766.
[56]Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-Ⅱ in human heart. Cardiovasc Res 2004,63(4):673-681.
[57]Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-Ⅱ in human heart in vitro. Br J Pharmacol 2001,132(1):5-9.
[58]Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-Ⅱ in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280(2):H925-928.
[59]Russell FD. Emerging roles of urotensin-Ⅱ in cardiovascular disease. Pharmacol Ther 2004, 103(3):223-243.
[60]Saetrum Opgaard O, Nothacker H, Ehlert FJ, et al. Human urotensin Ⅱ mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000,406(2):265-271.
[61]Tasaki K, Hori M, Ozaki H, et al. Mechanism of human urotensin Ⅱ-induced contraction in rat aorta. J Pharmacol Sci 2004,94(4):376-383.
[62]Rossowski WJ, Cheng BL, Taylor JE, et al. Human urotensin Ⅱ-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase:inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002,438(3):159-170.
[63]Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin Ⅱ-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001, 88(11):1102-1104.
[64]Wang YX, Ding YJ, Zhu YZ, et al. Role of PKC in the novel synergistic action of urotensin Ⅱ and angiotensin Ⅱ and in urotensin Ⅱ-induced vasoconstriction. Am J Physiol Heart Circ Physiol 2007,292(1):H348-359.
[65]Giebing G, Tolle M, Jurgensen J, et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin Ⅱ-mediated vasoconstriction. Circ Res 2005,97(7):707-715.
[66]Bohm F, Pernow J. Urotensin Ⅱ evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002,135(1):25-27.
[67]Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin Ⅱ do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002,53(2):341-347.
[68]Affolter JT, Newby DE, Wilkinson IB, et al. No effect on central or peripheral blood pressure of systemic urotensin Ⅱ infusion in humans. Br J Clin Pharmacol 2002,54(6):617-621.
[69]Sondermeijer B, Kompa A, Komesaroff P, et al. Effect of exogenous urotensin-Ⅱ on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005, 18(9 Pt 1):1195-1199.
[70]Zomer E, de Ridder I, Kompa A, et al. Effect of urotensin Ⅱ on skin microvessel tone in diabetic patients without heart failure or essential hypertension. Clin Exp Pharmacol Physiol 2008,35(10):1147-1150.
[71]Behm DJ, Doe CP, Johns DG, et al. Urotensin-Ⅱ:a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 2004,369(3):274-280.
[72]Lin Y, Tsuchihashi T, Matsumura K, et al. Central cardiovascular action of urotensin Ⅱ in spontaneously hypertensive rats. Hypertens Res 2003,26(10):839-845.
[73]Watson AM, Lambert GW, Smith KJ, et al. Urotensin Ⅱ acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003, 42(3):373-379.
[74]Lu Y, Zou CJ, Huang DW, et al. Cardiovascular effects of urotensin Ⅱ in different brain areas. Peptides 2002,23(9):1631-1635.
[75]Thompson JP, Watt P, Sanghavi S, et al. A comparison of cerebrospinal fluid and plasma urotensin Ⅱ concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia:a pilot study. Anesth Analg 2003,97(5):1501-1503.
[76]Rdzanek A, Filipiak K.J, Karpinski G, et al. Exercise urotensin Ⅱ dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 2006,110(2):175-178.
[77]Zeng ZP, Liu GQ, Li HZ, et al. The effects of urotensin-Ⅱ on proliferation of pheochromocytoma cells and mRNA expression of urotensin-Ⅱ and its receptor in pheochromocytoma tissues. Ann N Y Acad Sci 2006,1073:284-289.
[78]Yi L, Gu YH, Wang XL, et al. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res 2006,34(3):272-283.
[79]Ong KL, Wong LY, Cheung BM. The role of urotensin Ⅱ in the metabolic syndrome. Peptides 2008,29(5):859-867.
[80]Suzuki S, Wenyi Z, Hirai M, et al. Genetic variations at urotensin Ⅱ and urotensin Ⅱ receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004,25(10):1803-1808.
[81]Ong KL, Wong LY, Man YB, et al. Haplotypes in the urotensin Ⅱ gene and urotensin Ⅱ receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 2006,27(7):1659-1667.
[82]Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin Ⅱ and its increased urinary excretion in patients with Type 2 diabetes mellitus:association with progress of diabetic nephropathy. Peptides 2004,25(10):1809-1814.
[83]Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. Inhibition of insulin release by urotensin Ⅱ-a study on the perfused rat pancreas. Horm Metab Res 2001,33(6):379-381.
[84]Dai HY, Guo XG, Ge ZM, et al. Elevated expression of urotensin Ⅱ and its receptor in diabetic cardiomyopathy. J Diabetes Complications 2008,22(2):137-143.
[85]Sheridan MA, Plisetskaya EM, Bern HA, et al. Effects of somatostatin-25 and urotensin Ⅱ on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 1987,66(3):405-414.
[86]Sheridan MA, Bern HA. Both somatostatin and the caudal neuropeptide, urotensin Ⅱ, stimulate lipid mobilization from coho salmon liver incubated in vitro. Regul Pept 1986,14(4):333-344.
[87]Do-Rego JC, Chatenet D, Orta MH, et al. Behavioral effects of urotensin-Ⅱ centrally administered in mice. Psychopharmacology (Berl) 2005,183(1):103-117.
[88]Matsumoto Y, Abe M, Watanabe T, et al. Intracerebroventricular administration of urotensin Ⅱ promotes anxiogenic-like behaviors in rodents. Neurosci Lett 2004,358(2):99-102.
[89]Jiang Z, Michal JJ, Tobey DJ, et al. Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus. Int J Biol Sci 2008,4(2):96-102.
[90]Shiraishi Y, Watanabe T, Suguro T, et al. Chronic urotensin Ⅱ infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J Hypertens 2008, 26(10):1955-1965.
[91]Wang ZJ, Shi LB, Xiong ZW, et al. Alteration of vascular urotensin Ⅱ receptor in mice with apolipoprotein E gene knockout. Peptides 2006,27(4):858-863.
[92]Bousette N, D'Orleans-Juste P, Kiss RS, et al.Urotensin Ⅱ receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Circ Res 2009,105(7):686-695,619 p following 695.
[93]Rakowski E, Hassan GS, Dhanak D, et al. A role for urotensin Ⅱ in restenosis following balloon angioplasty:use of a selective UT receptor blocker. J Mol Cell Cardiol 2005,39(5):785-791.
[94]Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin Ⅱ levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007,20(2):211-217.
[95]Suguro T, Watanabe T, Kodate S, et al. Increased plasma urotensin-Ⅱ levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 2008, 115(11):327-334.
[96]Ban Y, Watanabe T, Suguro T, et al. Increased plasma urotensin-Ⅱ and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 2009,16(3):179-187.
[97]Heringlake M, Kox T, Uzun O, et al. The relationship between urotensin Ⅱ plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004,121(1-3):129-136.
[98]Fang SH, Li ZL, Wu HC, et al. [Clinical study of plasma urotensin Ⅱ in patients with coronary heart disease]. Di Yi Jun Yi Da Xue Xue Bao 2004,24(5):563-565.
[99]Katugampola SD, Kuc RE, Maguire JJ, et al. G-protein-coupled receptors in human atherosclerosis:comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-Ⅱ, apelin and ghrelin) receptors. Clin Sci (Lond) 2002,103 Suppl 48:171S-175S.
[100]Maguire JJ, Kuc RE, Kleinz MJ, et al. Immunocytochemical localization of the urotensin-Ⅱ receptor, UT, to rat and human tissues:relevance to function. Peptides 2008,29(5):735-742.
[101]Zhang Y, Li J, Cao J, et al. Effect of chronic hypoxia on contents of urotensin Ⅱ and its functional receptors in rat myocardium. Heart Vessels 2002,16(2):64-68.
[102]Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin Ⅱ on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003,93(3):246-253.
[103]Zou Y, Nagai R, Yamazaki T. Urotensin Ⅱ induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 2001,508(1):57-60.
[104]Gendron G, Simard B, Gobeil F, et al. Human urotensin-Ⅱ enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Physiol Pharmacol 2004,82(1):16-21.
[105]Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin Ⅱ on human endothelial cells. Atherosclerosis 2006,188(2):260-264.
[106]Wang H, Mehta JL, Chen K, et al. Human urotensin Ⅱ modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004, 44(5):577-581.
[107]Cirillo P, De Rosa S, Pacileo M, et al. Human urotensin Ⅱ induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells:an emerging role for urotensin Ⅱ in cardiovascular disease. J Thromb Haemost 2008,6(5):726-736.
[108]Watanabe T, Suguro T, Kanome T, et al. Human urotensin Ⅱ accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005,46(4):738-744.
[109]Matsusaka S, Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin Ⅱ. Naunyn Schmiedebergs Arch Pharmacol 2006,373(5):381-386.
[110]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001,104(1):16-18.
[111]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001,19(12):2191-2196.
[112]Watanabe T, Takahashi K, Kanome T, et al. Human urotensin-Ⅱ potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells:comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 2006,29(10):821-831.
[113]彭旭,尹航,汪丽蕙,等.尾加压素增加血管平滑肌细胞粘着斑激酶的含量和活力[J].生理学报2000,52(6)：455-458.
[114]Djordjevic T, BelAiba RS, Bonello S, et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005,25(3):519-525.
[115]Zhang YG, Li J, Li YG, et al. Urotensin Ⅱ induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J Hypertens 2008,26(6): 1119-1126.
[116]Chen YL, Liu JC, Loh SH, et al. Involvement of reactive oxygen species in urotensin Ⅱ-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 2008,593(1-3):24-29.
[117]Lescot E, Bureau R, Rault S. Nonpeptide Urotensin-Ⅱ receptor agonists and antagonists: review and structure-activity relationships. Peptides 2008,29(5):680-690.
[118]Ashton N. Renal and vascular actions of urotensin Ⅱ. Kidney Int 2006,70(4):624-629.
[119]Patacchini R, Santicioli P, Giuliani S, et al. Urantide:an ultrapotent urotensin Ⅱ antagonist peptide in the rat aorta. Br J Pharmacol 2003,140(7):1155-1158.
[120]Camarda V, Song W, Marzola E, et al. Urantide mimics urotensin-Ⅱ induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004,498(1-3):83-86.
[121]Clozel M, Binkert C, Birker-Robaczewska M, et al. Pharmacology of the urotensin-Ⅱ receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt):first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 2004,311(1):204-212.
[122]Douglas SA. Human urotensin-Ⅱ as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 2003,3(2):159-167.
[123]Herold CL, Behm DJ, Buckley PT, et al. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-Ⅱ receptors. Br J Pharmacol 2003,139(2): 203-207.
[124]Bousette N, Hu F, Ohlstein EH, et al. Urotensin-Ⅱ blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006, 41(2):285-295.
[125]Bousette N, Pottinger J, Ramli W, et al. Urotensin-Ⅱ receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006,27(11): 2919-2926.
[126]Bousette N, Giaid A. Urotensin-Ⅱ and cardiovascular diseases. Curr Hypertens Rep 2006, 8(6):479-483.
[127]Clozel M, Hess P, Qiu C, et al. The urotensin-Ⅱ receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006,316(3):1115-1121.
[128]Sidharta PN, Wagner FD, Bohnemeier H, et al. Pharmacodynamics and pharmacokinetics of the urotensin Ⅱ receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006,80(3):246-256.
[2]Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells:the missing link in atherosclerosis? J Mol Med 2004,82(10):671-677.
[3]Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997,275(5302):964-967.
[4]Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003,9(6):702-712.
[5]Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999,401(6750):282-286.
[6]Watanabe T, Arita S, Shiraishi Y, et al. Human urotensin Ⅱ promotes hypertension and atherosclerotic cardiovascular diseases. Curr Med Chem 2009,16(5):550-563.
[7]Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin Ⅱ on human endothelial cells. Atherosclerosis 2006,188(2):260-264.
[8]Wang H, Mehta JL, Chen K, et al. Human urotensin Ⅱ modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004,44(5):577-581.
[9]Cirillo P, De Rosa S, Pacileo M, et al. Human urotensin Ⅱ induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells:an emerging role for urotensin Ⅱ in cardiovascular disease. J Thromb Haemost 2008,6(5):726-736.
[10]Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999,85(3):221-228.
[11]Murohara T. Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. Trends Cardiovasc Med 2001,11(8):303-307.
[12]Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998,92(2):362-367.
[13]Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007,109(5):1801-1809.
[14]Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001,89(1):E1-7.
[15]Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993,69(5):508-517.
[16]Sharpe EE,3rd, Teleron AA, Li B, et al.Price J, et al. The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells. Am J Pathol 2006,168(5): 1710-1721.
[17]Casamassimi A, Balestrieri ML, Fiorito C, et al. Comparison between total endothelial progenitor cell isolation versus enriched Cd133+culture. J Biochem 2007,141(4):503-511.
[18]Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997,90(12):5002-5012.
[19]Mori M, Sugo T, Abe M, et al. Urotensin Ⅱ is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999,265(1):123-129.
[20]Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin Ⅱ:receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000,131(3):441-446.
[21]Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin Ⅱ and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001,19(12):2185-2190.
[22]Douglas SA, Ohlstein EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000,10(6):229-237.
[23]Maguire JJ, Davenport AP. Is urotensin-Ⅱ the new endothelin? Br J Pharmacol 2002, 137(5):579-588.
[24]Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-Ⅱ in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004,25(10):1767-1774.
[25]Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin Ⅱ and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004, 176(1):117-123.
[26]Douglas SA, Naselsky D, Ao Z, et al. Identification and pharmacological characterization of native, functional human urotensin-Ⅱ receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 2004,142(6):921-932.
[27]Guerrini R, Camarda V, Marzola E, et al. Structure-activity relationship study on human urotensin Ⅱ. J Pept Sci 2005,11(2):85-90.
[28]Liu Q, Pong SS, Zeng Z, et al. Identification of urotensin Ⅱ as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999, 266(1):174-178.
[29]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001,19(12):2191-2196.
[30]Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet 2002,359(9322):1990-1997.
[31]Richards AM, Charles C. Urotensin Ⅱ in the cardiovascular system. Peptides 2004,25(10): 1795-1802.
[32]Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-Ⅱ immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003,285(4): H1576-1581.
[33]Hongfang J, Cong B, Zhao B, et al. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 2006,78(12):1299-1309.
[34]Johns DG, Ao Z, Naselsky D, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy:effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004,370(4):238-250.
[35]Birker-Robaczewska M, Boukhadra C, Studer R, et al. The expression of urotensin Ⅱ receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 2003,23(4): 289-305.
[36]Segain JP, Rolli-Derkinderen M, Gervois N, et al. Urotensin Ⅱ is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007,179(2):901-909.
[37]Yang Y, Marcello M, Endris V, et al. MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp Cell Res 2006,312(12):2379-2393.
[38]Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996,15(9):2208-2216.
[39]Bhadriraju K, Elliott JT, Nguyen M, et al. Quantifying myosin light chain phosphorylation in single adherent cells with automated fluorescence microscopy. BMC Cell Biol 2007,8:43.
[40]Hartel FV, Rodewald CW, Aslam M, et al. Extracellular ATP induces assembly and activation of the myosin light chain phosphatase complex in endothelial cells. Cardiovasc Res 2007, 74(3):487-496.
[41]Zhu YC, Zhu YZ, Moore PK. The role of urotensin Ⅱ in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006,148(7):884-901.
[42]Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin Ⅱ-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001, 88(11):1102-1104.
[43]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001,104(1):16-18.
[44]Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003,9(11):1370-1376.
[45]Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol 2007,49(7):741-752.
[46]Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003,348(7):593-600.
[47]Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999,340(2):115-126.
[48]Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003, 23(7):1143-1151.
[49]Hassan GS, Douglas SA, Ohlstein EH, et al. Expression of urotensin-Ⅱ in human coronary atherosclerosis. Peptides 2005,26(12):2464-2472.
[50]Gendron G, Simard B, Gobeil F, et al. Human urotensin-Ⅱ enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Physiol Pharmacol 2004,82(1):16-21.
[51]Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation 2003,108(4):457-463.
[52]Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002,420(6916):629-635.
[53]Vicente-Manzanares M, Cabrero JR, Rey M, et al. A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1 alpha-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J Immunol 2002,168(1):400-410.
[54]Zhang YG, Li YG, Liu BG, et al. Urotensin Ⅱ accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol Sin 2007,28(1):36-43.
[55]Matsusaka S, Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin Ⅱ. Naunyn Schmiedebergs Arch Pharmacol 2006,373(5):381-386.
[56]Saetrum Opgaard O, Nothacker H, Ehlert FJ, et al. Human urotensin Ⅱ mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000,406(2):265-271.
[57]Tasaki K, Hori M, Ozaki H, et al. Mechanism of human urotensin Ⅱ-induced contraction in rat aorta. J Pharmacol Sci 2004,94(4):376-383.
[58]Rossowski WJ, Cheng BL, Taylor JE, et al. Human urotensin Ⅱ-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase:inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002,438(3):159-170.
[59]Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin Ⅱ is raised in hypertension. J Hypertens 2004,22(7):1341-1344.
[60]Khan SQ, Bhandari SS, Quinn P, et al. Urotensin Ⅱ is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007, 117(3):323-328.
[61]Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-Ⅱ-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004,94(1):93-97.
[62]Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation 2002,106(23):2877-2880.
[63]Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin Ⅱ levels in patients with diabetes mellitus. Clin Sci (Lond) 2003,104(1):1-5.
[64]Zoccali C, Mallamaci F, Benedetto FA, et al. Urotensin Ⅱ and cardiomyopathy in end-stage renal disease. Hypertension 2008,51(2):326-333.
[65]Heller J, Schepke M, Neef M, et al. Increased urotensin Ⅱ plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002,37(6):767-772.
[66]Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of Urotensin-Ⅱ in preeclampsia-eclampsia:a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol 2005,120(1):33-38.
[67]Gruson D, Rousseau MF, Ahn SA, et al. Circulating urotensin Ⅱ levels in moderate to severe congestive heart failure:its relations with myocardial function and well established neurohormonal markers. Peptides 2006,27(6):1527-1531.
[68]Charles CJ, Rademaker MT, Richards AM, et al. Urotensin Ⅱ:evidence for cardiac, hepatic and renal production. Peptides 2005,26(11):2211-2214.
[69]Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin Ⅱ in heart failure. Lancet 2002,360(9332):545-546.
[70]Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin Ⅱ and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006,19(5):505-510.
[71]Gold SJ, Thompson JP, Williams JP, et al. Does cigarette smoking increase plasma urotensin Ⅱ concentrations? Eur J Clin Pharmacol 2007,63(3):253-257.
[72]Li DY, Chen HJ, Staples ED, et al. Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions. J Cardiovasc Pharmacol Ther 2002,7(3):147-153.
[73]Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004,94(3):370-376.
[74]Chen H, Li D, Sawamura T, et al. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits:modulation by losartan. Biochem Biophys Res Commun 2000, 276(3):1100-1104.
[75]Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 2004,43(1):68-76.
[76]Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999,79(1): 215-262.
[77]Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin Ⅱ on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003,93(3):246-253.
[78]Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin Ⅱ causes fatal circulatory collapse in anesthesized monkeys in vivo:a "vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol 2004,286(3):H830-836.
[79]Djordjevic T, BelAiba RS, Bonello S, et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005, 25(3):519-525.
[80]Tamura K, Okazaki M, Tamura M, et al. Urotensin Ⅱ-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells:involvement of cell adhesion-mediated integrin signaling. Life Sci 2003,72(9):1049-1060.
[81]孙正浩,张孙曦,李菊香,等.钙信号在尾加压素Ⅱ促血管平滑肌增殖中的作用[J].北京大学学报(医学版)2002,34(3)：261-265.
[1]Balment RJ, Song W, Ashton N. Urotensin Ⅱ:ancient hormone with new functions in vertebrate body fluid regulation. Ann N Y Acad Sci 2005,1040:66-73.
[2]Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999,401(6750):282-286.
[3]Douglas SA, Naselsky D, Ao Z, et al. Identification and pharmacological characterization of native, functional human urotensin-Ⅱ receptors in rhabdomyosarcoma cell lines. Br J Pharmacol 2004,142(6):921-932.
[4]Mori M, Sugo T, Abe M, et al. Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999,265(1):123-129.
[5]Douglas SA, Ohlstein EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000,10(6):229-237.
[6]Russell FD, Kearns P, Toth I, et al. Urotensin-Ⅱ-converting enzyme activity of furin and trypsin in human cells in vitro. J Pharmacol Exp Ther 2004,310(1):209-214.
[7]Wenyi Z, Suzuki S, Hirai M, et al. Role of urotensin Ⅱ gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003,46(7):972-976.
[8]Protopopov A, Kashuba V, Podowski R, et al. Assignment of the GPR14 gene coding for the G-protein-coupled receptor 14 to human chromosome 17q25.3 by fluorescent in situ hybridization. Cytogenet Cell Genet 2000,88(3-4):312-313.
[9]Guerrini R, Camarda V, Marzola E, et al. Structure-activity relationship study on human urotensin Ⅱ. J Pept Sci 2005,11(2):85-90.
[10]Maguire JJ, Davenport AP. Is urotensin-Ⅱ the new endothelin? Br J Pharmacol 2002,137(5): 79-588.
[11]Maguire JJ, Kuc RE, Wiley KE, et al. Cellular distribution of immunoreactive urotensin-Ⅱ in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004,25(10):1767-1774.
[12]Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin Ⅱ and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004,176(1): 17-123.
[13]Xu S, Jiang H, Wu B, et al. Urotensin Ⅱ induces migration of endothelial progenitor cells via activation of the RhoA/Rho kinase pathway. Tohoku J Exp Med 2009,219(4):283-288.
[14]Richards AM, Charles C.:Urotensin Ⅱ in the cardiovascular system. Peptides 2004,25(10): 1795-1802.
[15]Russell FD, Meyers D, Galbraith AJ, et al. Elevated plasma levels of human urotensin-Ⅱ immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003,285(4): 1576-1581.
[16]Hongfang J, Cong B, Zhao B, et al. Effects of hydrogen sulfide on hypoxic pulmonary vascular structural remodeling. Life Sci 2006,78(12):1299-1309.
[17]Johns DG, Ao Z, Naselsky D, et al.Herold CL, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy:effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004,370(4):238-250.
[18]Birker-Robaczewska M, Boukhadra C, Studer R, et al. The expression of urotensin Ⅱ receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 2003,23(4): 89-305.
[19]Segain JP, Rolli-Derkinderen M, Gervois N, et al. Urotensin Ⅱ is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007,179(2):901-909.
[20]Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin Ⅱ is raised in hypertension. J Hypertens 2004,22(7):1341-1344.
[21]Khan SQ, Bhandari SS, Quinn P, et al. Urotensin Ⅱ is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007,117(3): 23-328.
[22]Lapp H, Boerrigter G, Costello-Boerrigter LC, et al. Elevated plasma human urotensin-Ⅱ-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 2004,94(1):93-97.
[23]Ng LL, Loke I, O'Brien RJ, et al.S Plasma urotensin in human systolic heart failure. Circulation 2002,106(23):2877-2880.
[24]Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin Ⅱ levels in patients with diabetes mellitus. Clin Sci (Lond) 2003,104(1):1-5.
[25]Zoccali C, Mallamaci F, Benedetto FA, et al. Urotensin Ⅱ and cardiomyopathy in end-stage renal disease. Hypertension 2008,51(2):326-333.
[26]Heller J, Schepke M, Neef M, et al. Increased urotensin Ⅱ plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002,37(6):767-772.
[27]Balat O, Aksoy F, Kutlar I, et al. Increased plasma levels of Urotensin-Ⅱ in preeclampsia-clampsia:a new mediator in pathogenesis? Eur J Obstet Gynecol Reprod Biol 2005,120(1): 3-38.
[28]Gruson D, Rousseau MF, Ahn SA, et al. Circulating urotensin Ⅱ levels in moderate to severe congestive heart failure:its relations with myocardial function and well established neurohormonal markers. Peptides 2006,27(6):1527-1531.
[29]Charles CJ, Rademaker MT, Richards AM, et al. Urotensin Ⅱ:evidence for cardiac, hepatic and renal production. Peptides 2005,26(11):2211-2214.
[30]Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin Ⅱ in heart failure. Lancet 2002,360(9332):545-546.
[31]Mallamaci F, Cutrupi S, Pizzini P, et al. Urotensin Ⅱ and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006,19(5):505-510.
[32]Gold SJ, Thompson JP, Williams JP, et al. Does cigarette smoking increase plasma urotensin Ⅱ concentrations? Eur J Clin Pharmacol 2007,63(3):253-257.
[33]Gibson A. Complex effects of Gillichthys urotensin Ⅱ on rat aortic strips. Br J Pharmacol 1987, 91(1):205-212.
[34]Yoshimoto S, Ishizaki Y, Sasaki T, et al. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991,22(3):378-383.
[35]Wagner OF, Christ G, Wojta J, et al.Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR:Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992,267(23):16066-16068.
[36]Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994, 23(6):1427-1433.
[37]Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin Ⅱ. Lancet 2002,359(9322):1990-1997.
[38]Hassan GS, Douglas SA, Ohlstein EH, et al. Expression of urotensin-Ⅱ in human coronary atherosclerosis. Peptides 2005,26(12):2464-2472.
[39]Kemp W, Krum H, Colman J, et al. Urotensin Ⅱ:a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007,27(9):1232-1239.
[40]Coulouarn Y, Lihrmann I, Jegou S, et al. Cloning of the cDNA encoding the urotensin Ⅱ precursor in frog and human reveals intense expression of the urotensin Ⅱ gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 1998,95(26):15803-15808.
[41]Nothacker HP, Wang Z, McNeill AM, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999, 1(6):383-385.
[42]Shenouda A, Douglas SA, Ohlstein EH, et al. Localization of urotensin-Ⅱ immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002,50(7):885-889.
[43]Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin Ⅱ and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001,19(12):2185-2190.
[44]Langham RG, Kelly DJ, Gow RM, et al. Increased expression of urotensin Ⅱ and urotensin Ⅱ receptor in human diabetic nephropathy. Am J Kidney Dis 2004,44(5):826-831.
[45]Totsune K, Takahashi K, Arihara Z, et al. Role of urotensin Ⅱ in patients on dialysis. Lancet 2001,358(9284):810-811.
[46]Mosenkis A, Danoff TM, Aiyar N, et al. Human urotensin Ⅱ in the plasma of anephric subjects. Nephrol Dial Transplant 2007,22(4):1269-1270.
[47]MacLean MR, Alexander D, Stirrat A, et al. Contractile responses to human urotensin-Ⅱ in rat and human pulmonary arteries:effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000,130(2):201-204.
[48]Djordjevic T, Gorlach A.:Urotensin-Ⅱ in the lung:a matter for vascular remodelling and pulmonary hypertension? Thromb Haemost 2007,98(5):952-962.
[49]Bottrill FE, Douglas SA, Hiley CR, et al. Human urotensin-Ⅱ is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000,130(8):1865-1870.
[50]Douglas SA, Sulpizio AC, Piercy V, et al. Differential vasoconstrictor activity of human urotensin-Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000,131(7):1262-1274.
[51]Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin Ⅱ:receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000,131(3):441-446.
[52]Camarda V, Rizzi A, Calo G, et al. Effects of human urotensin Ⅱ in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 2002,365(2):141-149.
[53]Behm DJ, Harrison SM, Ao Z, et al. Deletion of the UT receptor gene results in the selective loss of urotensin-Ⅱ contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003,139(2):464-472.
[54]Ishihata A, Ogaki T, Aita T, et al. Role of prostaglandins in urotensin Ⅱ-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 2005,523(1-3):119-126.
[55]Lacza Z, D WB. Urotensin-Ⅱ is a nitric oxide-dependent vasodilator in the pial arteries of the newborn pig. Life Sci 2006,78(23):2763-2766.
[56]Russell FD, Molenaar P. Investigation of signaling pathways that mediate the inotropic effect of urotensin-Ⅱ in human heart. Cardiovasc Res 2004,63(4):673-681.
[57]Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin-Ⅱ in human heart in vitro. Br J Pharmacol 2001,132(1):5-9.
[58]Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-Ⅱ in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280(2):H925-928.
[59]Russell FD. Emerging roles of urotensin-Ⅱ in cardiovascular disease. Pharmacol Ther 2004, 103(3):223-243.
[60]Saetrum Opgaard O, Nothacker H, Ehlert FJ, et al. Human urotensin Ⅱ mediates vasoconstriction via an increase in inositol phosphates. Eur J Pharmacol 2000,406(2):265-271.
[61]Tasaki K, Hori M, Ozaki H, et al. Mechanism of human urotensin Ⅱ-induced contraction in rat aorta. J Pharmacol Sci 2004,94(4):376-383.
[62]Rossowski WJ, Cheng BL, Taylor JE, et al. Human urotensin Ⅱ-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase:inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002,438(3):159-170.
[63]Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin Ⅱ-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001, 88(11):1102-1104.
[64]Wang YX, Ding YJ, Zhu YZ, et al. Role of PKC in the novel synergistic action of urotensin Ⅱ and angiotensin Ⅱ and in urotensin Ⅱ-induced vasoconstriction. Am J Physiol Heart Circ Physiol 2007,292(1):H348-359.
[65]Giebing G, Tolle M, Jurgensen J, et al. Arrestin-independent internalization and recycling of the urotensin receptor contribute to long-lasting urotensin Ⅱ-mediated vasoconstriction. Circ Res 2005,97(7):707-715.
[66]Bohm F, Pernow J. Urotensin Ⅱ evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002,135(1):25-27.
[67]Wilkinson IB, Affolter JT, de Haas SL, et al. High plasma concentrations of human urotensin Ⅱ do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002,53(2):341-347.
[68]Affolter JT, Newby DE, Wilkinson IB, et al. No effect on central or peripheral blood pressure of systemic urotensin Ⅱ infusion in humans. Br J Clin Pharmacol 2002,54(6):617-621.
[69]Sondermeijer B, Kompa A, Komesaroff P, et al. Effect of exogenous urotensin-Ⅱ on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005, 18(9 Pt 1):1195-1199.
[70]Zomer E, de Ridder I, Kompa A, et al. Effect of urotensin Ⅱ on skin microvessel tone in diabetic patients without heart failure or essential hypertension. Clin Exp Pharmacol Physiol 2008,35(10):1147-1150.
[71]Behm DJ, Doe CP, Johns DG, et al. Urotensin-Ⅱ:a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 2004,369(3):274-280.
[72]Lin Y, Tsuchihashi T, Matsumura K, et al. Central cardiovascular action of urotensin Ⅱ in spontaneously hypertensive rats. Hypertens Res 2003,26(10):839-845.
[73]Watson AM, Lambert GW, Smith KJ, et al. Urotensin Ⅱ acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003, 42(3):373-379.
[74]Lu Y, Zou CJ, Huang DW, et al. Cardiovascular effects of urotensin Ⅱ in different brain areas. Peptides 2002,23(9):1631-1635.
[75]Thompson JP, Watt P, Sanghavi S, et al. A comparison of cerebrospinal fluid and plasma urotensin Ⅱ concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia:a pilot study. Anesth Analg 2003,97(5):1501-1503.
[76]Rdzanek A, Filipiak K.J, Karpinski G, et al. Exercise urotensin Ⅱ dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 2006,110(2):175-178.
[77]Zeng ZP, Liu GQ, Li HZ, et al. The effects of urotensin-Ⅱ on proliferation of pheochromocytoma cells and mRNA expression of urotensin-Ⅱ and its receptor in pheochromocytoma tissues. Ann N Y Acad Sci 2006,1073:284-289.
[78]Yi L, Gu YH, Wang XL, et al. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res 2006,34(3):272-283.
[79]Ong KL, Wong LY, Cheung BM. The role of urotensin Ⅱ in the metabolic syndrome. Peptides 2008,29(5):859-867.
[80]Suzuki S, Wenyi Z, Hirai M, et al. Genetic variations at urotensin Ⅱ and urotensin Ⅱ receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004,25(10):1803-1808.
[81]Ong KL, Wong LY, Man YB, et al. Haplotypes in the urotensin Ⅱ gene and urotensin Ⅱ receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 2006,27(7):1659-1667.
[82]Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin Ⅱ and its increased urinary excretion in patients with Type 2 diabetes mellitus:association with progress of diabetic nephropathy. Peptides 2004,25(10):1809-1814.
[83]Silvestre RA, Rodriguez-Gallardo J, Egido EM, et al. Inhibition of insulin release by urotensin Ⅱ-a study on the perfused rat pancreas. Horm Metab Res 2001,33(6):379-381.
[84]Dai HY, Guo XG, Ge ZM, et al. Elevated expression of urotensin Ⅱ and its receptor in diabetic cardiomyopathy. J Diabetes Complications 2008,22(2):137-143.
[85]Sheridan MA, Plisetskaya EM, Bern HA, et al. Effects of somatostatin-25 and urotensin Ⅱ on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 1987,66(3):405-414.
[86]Sheridan MA, Bern HA. Both somatostatin and the caudal neuropeptide, urotensin Ⅱ, stimulate lipid mobilization from coho salmon liver incubated in vitro. Regul Pept 1986,14(4):333-344.
[87]Do-Rego JC, Chatenet D, Orta MH, et al. Behavioral effects of urotensin-Ⅱ centrally administered in mice. Psychopharmacology (Berl) 2005,183(1):103-117.
[88]Matsumoto Y, Abe M, Watanabe T, et al. Intracerebroventricular administration of urotensin Ⅱ promotes anxiogenic-like behaviors in rodents. Neurosci Lett 2004,358(2):99-102.
[89]Jiang Z, Michal JJ, Tobey DJ, et al. Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus. Int J Biol Sci 2008,4(2):96-102.
[90]Shiraishi Y, Watanabe T, Suguro T, et al. Chronic urotensin Ⅱ infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. J Hypertens 2008, 26(10):1955-1965.
[91]Wang ZJ, Shi LB, Xiong ZW, et al. Alteration of vascular urotensin Ⅱ receptor in mice with apolipoprotein E gene knockout. Peptides 2006,27(4):858-863.
[92]Bousette N, D'Orleans-Juste P, Kiss RS, et al.Urotensin Ⅱ receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype. Circ Res 2009,105(7):686-695,619 p following 695.
[93]Rakowski E, Hassan GS, Dhanak D, et al. A role for urotensin Ⅱ in restenosis following balloon angioplasty:use of a selective UT receptor blocker. J Mol Cell Cardiol 2005,39(5):785-791.
[94]Suguro T, Watanabe T, Ban Y, et al. Increased human urotensin Ⅱ levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007,20(2):211-217.
[95]Suguro T, Watanabe T, Kodate S, et al. Increased plasma urotensin-Ⅱ levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 2008, 115(11):327-334.
[96]Ban Y, Watanabe T, Suguro T, et al. Increased plasma urotensin-Ⅱ and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 2009,16(3):179-187.
[97]Heringlake M, Kox T, Uzun O, et al. The relationship between urotensin Ⅱ plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 2004,121(1-3):129-136.
[98]Fang SH, Li ZL, Wu HC, et al. [Clinical study of plasma urotensin Ⅱ in patients with coronary heart disease]. Di Yi Jun Yi Da Xue Xue Bao 2004,24(5):563-565.
[99]Katugampola SD, Kuc RE, Maguire JJ, et al. G-protein-coupled receptors in human atherosclerosis:comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-Ⅱ, apelin and ghrelin) receptors. Clin Sci (Lond) 2002,103 Suppl 48:171S-175S.
[100]Maguire JJ, Kuc RE, Kleinz MJ, et al. Immunocytochemical localization of the urotensin-Ⅱ receptor, UT, to rat and human tissues:relevance to function. Peptides 2008,29(5):735-742.
[101]Zhang Y, Li J, Cao J, et al. Effect of chronic hypoxia on contents of urotensin Ⅱ and its functional receptors in rat myocardium. Heart Vessels 2002,16(2):64-68.
[102]Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin Ⅱ on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003,93(3):246-253.
[103]Zou Y, Nagai R, Yamazaki T. Urotensin Ⅱ induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 2001,508(1):57-60.
[104]Gendron G, Simard B, Gobeil F, et al. Human urotensin-Ⅱ enhances plasma extravasation in specific vascular districts in Wistar rats. Can J Physiol Pharmacol 2004,82(1):16-21.
[105]Shi L, Ding W, Li D, et al. Proliferation and anti-apoptotic effects of human urotensin Ⅱ on human endothelial cells. Atherosclerosis 2006,188(2):260-264.
[106]Wang H, Mehta JL, Chen K, et al. Human urotensin Ⅱ modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 2004, 44(5):577-581.
[107]Cirillo P, De Rosa S, Pacileo M, et al. Human urotensin Ⅱ induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells:an emerging role for urotensin Ⅱ in cardiovascular disease. J Thromb Haemost 2008,6(5):726-736.
[108]Watanabe T, Suguro T, Kanome T, et al. Human urotensin Ⅱ accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 2005,46(4):738-744.
[109]Matsusaka S, Wakabayashi I. Enhancement of vascular smooth muscle cell migration by urotensin Ⅱ. Naunyn Schmiedebergs Arch Pharmacol 2006,373(5):381-386.
[110]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001,104(1):16-18.
[111]Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001,19(12):2191-2196.
[112]Watanabe T, Takahashi K, Kanome T, et al. Human urotensin-Ⅱ potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells:comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 2006,29(10):821-831.
[113]彭旭,尹航,汪丽蕙,等.尾加压素增加血管平滑肌细胞粘着斑激酶的含量和活力[J].生理学报2000,52(6)：455-458.
[114]Djordjevic T, BelAiba RS, Bonello S, et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005,25(3):519-525.
[115]Zhang YG, Li J, Li YG, et al. Urotensin Ⅱ induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J Hypertens 2008,26(6): 1119-1126.
[116]Chen YL, Liu JC, Loh SH, et al. Involvement of reactive oxygen species in urotensin Ⅱ-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 2008,593(1-3):24-29.
[117]Lescot E, Bureau R, Rault S. Nonpeptide Urotensin-Ⅱ receptor agonists and antagonists: review and structure-activity relationships. Peptides 2008,29(5):680-690.
[118]Ashton N. Renal and vascular actions of urotensin Ⅱ. Kidney Int 2006,70(4):624-629.
[119]Patacchini R, Santicioli P, Giuliani S, et al. Urantide:an ultrapotent urotensin Ⅱ antagonist peptide in the rat aorta. Br J Pharmacol 2003,140(7):1155-1158.
[120]Camarda V, Song W, Marzola E, et al. Urantide mimics urotensin-Ⅱ induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 2004,498(1-3):83-86.
[121]Clozel M, Binkert C, Birker-Robaczewska M, et al. Pharmacology of the urotensin-Ⅱ receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt):first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 2004,311(1):204-212.
[122]Douglas SA. Human urotensin-Ⅱ as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? Curr Opin Pharmacol 2003,3(2):159-167.
[123]Herold CL, Behm DJ, Buckley PT, et al. The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-Ⅱ receptors. Br J Pharmacol 2003,139(2): 203-207.
[124]Bousette N, Hu F, Ohlstein EH, et al. Urotensin-Ⅱ blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006, 41(2):285-295.
[125]Bousette N, Pottinger J, Ramli W, et al. Urotensin-Ⅱ receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006,27(11): 2919-2926.
[126]Bousette N, Giaid A. Urotensin-Ⅱ and cardiovascular diseases. Curr Hypertens Rep 2006, 8(6):479-483.
[127]Clozel M, Hess P, Qiu C, et al. The urotensin-Ⅱ receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006,316(3):1115-1121.
[128]Sidharta PN, Wagner FD, Bohnemeier H, et al. Pharmacodynamics and pharmacokinetics of the urotensin Ⅱ receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006,80(3):246-256.